For 139 years, the Boehringer family has resisted every invitation to take their pharmaceutical company public. That decision,renewed across five generations,has produced one of the world’s largest private companies: $28.9 billion in 2024 revenue, 54,543 employees, and a research budget exceeding $5 billion a year, all without issuing a single share to public markets.
In an industry where capital markets fund the next blockbuster, Boehringer Ingelheim has run one of the longest experiments in pharmaceutical independence. Albert Boehringer founded the company in 1885 in Ingelheim am Rhein, a small town in western Germany. His descendants still own it. There has been no IPO, no spin-off, no SPAC. The company that produced €26.8 billion in net sales in 2024 remains, structurally, a family business.
That structure has consequences. Public pharmaceutical companies answer to quarterly earnings calls. Analysts parse their R&D pipelines for near-term catalysts. Management teams face pressure to cut programmes that will not produce revenue within the current CEO’s tenure. Boehringer faces none of this. Its R&D investment exceeded €5 billion in 2022 alone, a figure that represented roughly one-fifth of total revenue. The family accepts that ratio because they measure returns across decades, not quarters.
The result is a company that behaves differently from its listed peers. When nintedanib, a triple angiokinase inhibitor, showed promise in idiopathic pulmonary fibrosis,a disease with a small patient population and limited commercial ceiling,Boehringer pursued it. A publicly traded company might have shelved the programme in favour of a larger-market opportunity. Boehringer brought Ofev to market. It became a standard of care for IPF and later expanded into other progressive fibrosing interstitial lung diseases. That trajectory, from niche indication to expanded label, is the kind of development arc that private ownership makes possible.
India is part of this structure. Boehringer Ingelheim India Private Limited operates as a subsidiary,private limited, not listed on any Indian exchange. The company operates in India the same way it operates everywhere: quietly, without the disclosure obligations that come with public listing, and with a planning horizon that extends well beyond the next financial year.
The partnership that produced Jardiance is one of the more consequential deals in modern cardiology. In 2011, Boehringer Ingelheim and Eli Lilly signed an agreement to co-develop and co-commercialise a portfolio of diabetes therapies. The centrepiece was empagliflozin, a sodium-glucose co-transporter 2 inhibitor that worked by causing the kidneys to excrete excess glucose in urine. The mechanism was simple. The implications were not.
SGLT2 inhibitors were initially developed as diabetes drugs. Empagliflozin lowered blood sugar. That was the regulatory thesis. But when the EMPA-REG OUTCOME trial reported results in 2015, the data showed something the diabetes world had not expected: patients on empagliflozin had a 38 per cent relative risk reduction in cardiovascular death compared to placebo. A diabetes drug was saving hearts. The finding reshaped clinical practice. For the first time, endocrinologists were prescribing a glucose-lowering agent primarily for its cardiovascular benefit.
Jardiance subsequently expanded into heart failure,in patients with and without diabetes,and chronic kidney disease. The molecule that Boehringer originally developed as a diabetes therapy became one of the most important cardiovascular drugs of the decade. The Lilly partnership gave Boehringer commercial reach it could not have achieved alone: Lilly’s sales infrastructure in the United States and its established relationships with cardiologists and primary care physicians complemented Boehringer’s discovery and development capabilities.
The Jardiance franchise contributed significantly to the Human Pharma segment, which accounted for 81.8 per cent of Boehringer’s €26.8 billion in 2024 net sales. That single product line illustrates why Boehringer’s decision to remain private has worked commercially: the company had the patience to pursue a molecule through an initial indication, wait for the cardiovascular outcome data, and then systematically expand the label into adjacent diseases. The entire arc, from first synthesis to heart failure approval, took more than a decade.
Between 2000 and 2026, Boehringer Ingelheim filed 912 patent applications at the Indian Patent Office. Of those, 103 were granted. The numbers place it ninth among OPPI member companies in India,behind the largest multinationals with deeper Indian operations, but meaningfully ahead of dozens of companies that treat India as a distribution market rather than an intellectual property jurisdiction.
The filing pattern reveals something about how Boehringer thinks about India. A company that simply imports finished products into a market does not file 912 patents there. Patent filings in India signal that the company expects its innovations to face generic competition in the Indian market and is willing to invest in legal protection. Each filing requires Indian patent counsel, prosecution strategy tailored to Indian Patent Office practice, and the ongoing maintenance fees that keep a granted patent alive for its full term.
The 103 grants from 912 filings,a grant rate of roughly 11 per cent,reflects the well-documented rigour of the Indian Patent Office, which applies Section 3(d) of the Indian Patents Act to reject applications that do not demonstrate enhanced efficacy over known substances. Boehringer’s willingness to continue filing at this volume, despite a selective granting environment, suggests the company views Indian patent protection as strategically necessary for its key molecules, including the compounds underlying Jardiance, Ofev, Pradaxa, and Spiriva.
Most pharmaceutical companies operate in one kingdom: human medicine. Boehringer Ingelheim operates in two. In 2024, Human Pharma accounted for 81.8 per cent of net sales and Animal Health for 17.7 per cent. A biopharmaceutical contract manufacturing division contributed the remainder. Among OPPI member companies operating in India, this dual structure is unique.
The Animal Health business is not a peripheral division. It is a global franchise with products spanning companion animals and livestock across parasiticides, vaccines, and anti-infectives. The business serves veterinarians, farmers, and pet owners in markets where the line between human and animal health is increasingly blurred. Boehringer’s work in animal vaccines has direct relevance to zoonotic disease surveillance, and the company has argued publicly that its “One Health” approach,treating human and animal health as interconnected systems,gives it scientific advantages that pure human-pharma companies lack.
The proportions have shifted over time. In 2021, Human Pharma represented 74 per cent of revenue and Animal Health 21 per cent. By 2024, Human Pharma had grown to 81.8 per cent while Animal Health contracted to 17.7 per cent. The shift reflects the commercial success of Jardiance and other Human Pharma products rather than any decline in the animal business. But it also reveals a tension inherent in the dual model: when one kingdom grows faster than the other, the slower kingdom risks becoming an afterthought in capital allocation. Boehringer, to its credit, has continued to invest in both.
The contract manufacturing division,the third, smallest segment at roughly 4 per cent in 2021,produces biopharmaceuticals for other companies. It is an unusual business for a company of Boehringer’s size: effectively, the company manufactures its competitors’ drugs. But the contract manufacturing operation generates revenue from excess capacity, maintains relationships across the industry, and keeps Boehringer’s production infrastructure running at high utilisation rates. It is a pragmatic business, not a glamorous one.
Sources: Boehringer Ingelheim Annual Reports 2021–2024. Indian Patent Office (patent filing data). OPPI member directory.